Core Insights - The VALIANT trial for verekitug showed significant reductions in the annualized asthma exacerbation rate (AAER) by 56% for the 100 mg quarterly dosing and 39% for the 400 mg biannual dosing compared to placebo [2] - The drug demonstrated clinically meaningful improvements in lung function and was well-tolerated, with over 90% of eligible patients transitioning to a long-term extension study [2] - The company plans to initiate registrational trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) following regulatory interactions [5] Clinical Trial Results - At week 60, verekitug suppressed exhaled nitric oxide (FeNO) by 20.4 ppb (p<0.0003) for the 100 mg quarterly group and by 26.3 ppb (p<0.0001) for the 400 mg biannual group, representing mean reductions of 43.5% and 44.9% from baseline, respectively [3] - A low-dose treatment group (100 mg biannual) showed a statistically significant effect on AAER but lacked consistent improvements in other endpoints [4] - Statistically significant placebo-adjusted improvements in FEV1 and FeNO were observed at week 24 for both dosing regimens [4] Stock Performance and Analyst Consensus - The stock is currently trading 10.2% above its 20-day simple moving average (SMA) and 30.5% above its 100-day SMA, indicating strong short-term momentum [6] - Over the past 12 months, shares have surged 292.24%, and they are closer to their 52-week highs than lows [6] - The stock carries an Outperform Rating with an average price forecast of $49.00, with recent analyst targets ranging from $40.00 to $51.00 [8]
Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts